Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C98838
http://purl.obolibrary.org/obo/NCIT_C98838
|
|---|---|
| Preferred Name | Poziotinib |
| Definitions |
An orally bioavailable, quinazoline-based, irreversible pan-epidermal growth factor receptor (EGFR or HER) inhibitor, with potential antineoplastic activity. Upon oral administration, poziotinib inhibits EGFR (HER1 or ErbB1), HER2 and HER4, thereby inhibiting proliferation of tumor cells in which these receptors are overexpressed and/or mutated. EGFRs, cell surface receptor tyrosine kinases upregulated or mutated in a variety of cancer cell types, play key roles in cellular proliferation and survival.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally bioavailable, quinazoline-based, irreversible pan-epidermal growth factor receptor (EGFR or HER) inhibitor, with potential antineoplastic activity. Upon oral administration, poziotinib inhibits EGFR (HER1 or ErbB1), HER2 and HER4, thereby inhibiting proliferation of tumor cells in which these receptors are overexpressed and/or mutated. EGFRs, cell surface receptor tyrosine kinases upregulated or mutated in a variety of cancer cell types, play key roles in cellular proliferation and survival. |
|---|---|
| prefLabel | Poziotinib
|
| label | Poziotinib
|
| PDQ_Closed_Trial_Search_ID | 715507
|
| code | C98838
|
| Has_Target | |
| prefixIRI | NCIT:C98838
|
| in_subset |
See more
See less
|
| Display_Name | Poziotinib
|
| Preferred_Name | Poziotinib
|
| FDA_UNII_Code | OEI6OOU6IK
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Poziotinib
|
| CAS_Registry | 1092364-38-9
|
| NCI_Drug_Dictionary_ID | 715507
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 715507
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C3180480
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |